-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPIV-110 in Ductal Carcinoma In Situ
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TPIV-110 in Ductal Carcinoma In Situ Drug Details: TPIV-110 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AVE-1642 in Graves’ Ophthalmopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AVE-1642 in Graves' Ophthalmopathy Drug Details: AVE-1642 is under development for Grave's ophthalmopathy (thyroid eye...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naratuximab Emtansine in Non-Hodgkin Lymphoma Drug Details:Naratuximab emtansine is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naratuximab Emtansine in Follicular Lymphoma Drug Details:Naratuximab emtansine is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Mantle Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naratuximab Emtansine in Mantle Cell Lymphoma Drug Details:Naratuximab emtansine is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Marginal Zone B-cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naratuximab Emtansine in Marginal Zone B-cell Lymphoma Drug Details:Naratuximab emtansine is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPIV-200 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPIV-200 in Triple-Negative Breast Cancer (TNBC)Drug Details:TPIV-200 is under development for the treatment of triple negative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma Drug Details: Naratuximab emtansine is under development for...
-
Sector Analysis
New![]()
India Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
India Source Tourism Market Report Overview The India source tourism market witnessed 17.4 million outbound trips in 2022. The domestic travel in the country was 1.9 billion in the same year. The fast growth in outbound tourism from India is due to the increasing middle class and tourists wanting to venture further afield, paired with flexibility in visa and entry requirements for different destinations has helped many Indians explore and experience many different countries. In 2022, the top international destinations...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naratuximab Emtansine in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drug Details:Naratuximab emtansine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) Drug Details: Mirvetuximab Soravtansine (Elahere, Mirvetuximab Soravtansine-GYNX) is...
-
Sector Analysis
New![]()
Australia Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
Australia Source Tourism Market Report Overview The Australia source tourism market witnessed 6.61 million outbound trips in 2022. Outbound trips from Australia were severely impacted due to COVID-19. However, the tourism sector witnessed a significant recovery post the pandemic to encourage domestic travel consequently increasing the overall expenditure during 2022. Australia’s domestic travel reached its highest in 2022 post the pandemic, reaching a total of 100.47 million trips. In overall domestic trips, leisure purposes contribute the largest share. The Australia source...
-
Sector Analysis
New![]()
South Africa Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
South Africa Source Tourism Market Report Overview The South Africa source tourism market witnessed 4.06 million outbound trips in 2022. The domestic travel in the country was 51.1 million in the same year. International travel recovery from South Africa is expected to grow consistently, with projections indicating that it may cross pre-pandemic levels by the end of 2023 itself. The South African tourism market is going to rely heavily on visiting friends and relatives (VFR) and leisure travel to be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Endometrial Cancer Drug Details: Mirvetuximab Soravtansine (Elahere, Mirvetuximab Soravtansine-GYNX) is an immunoconjugate...
-
Sector Analysis
New![]()
Japan Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
Japan Source Tourism Market Report Overview The Japan source tourism market witnessed 2.58 million outbound trips in 2022. 2022 saw a significant rebound in the Japanese outbound tourist market, following the difficult years of the COVID-19 pandemic. Japanese travelers have a keen interest in venturing out to international destinations once more. The recent surge can be attributed to the higher vaccination rates, relaxed travel restrictions, and the strong desire for travel among the Japanese population. The Japan source tourism market...
-
Sector Analysis
![]()
France Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
GlobalData’s Tourism Source Market Insight: France report provides a thorough insight into the French domestic and outbound tourism market. The report looks at the profiles of French tourists and summarizes the key reasons that they travel. The report offers an in-depth analysis of traveler flows, spending patterns, main destination markets and current and future opportunities for tourism businesses seeking to tap into the French outbound travel market.
-
Sector Analysis
![]()
Philippines Sports Broadcasting Media (Television and Telecommunications) Landscape
Philippines Sports Broadcasting Media Market Report Overview The Philippines telecom and pay-TV services market size was estimated at $8.2 billion in 2022 and is expected to witness a CAGR of more than 2% during the forecast period, supported by mobile data and fixed broadband segments. Philippines Sports Broadcasting Media Market Outlook 2022-2027 ($ Billion) Buy the Full Report to Know More About the Philippines Sports Broadcasting Media Market Forecast, Download a Free Report Sample The Philippines sports broadcasting media market...
-
Sector Analysis
![]()
United States (US) Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
US Source Tourism Market Report Overview The US source tourism market witnessed 94.4 million outbound trips and 1.594 billion domestic trips in 2022. International travel recovery from the US is expected to grow consistently, with projections indicating that it may cross pre-pandemic levels by 2023. Traveling for leisure and visiting friends and relatives (VFR) is helping the tourism industry recover post the pandemic. Additionally, the share of business travel is increasing steadily both domestically and internationally. Economic losses during the...
-
Company Insights
![]()
Insurance Australia Group – Digital Transformation Strategies
Insurance Australia Group (IAG) Digital Transformation Strategies Report Overview Insurance Australia Group (IAG) is tapping into key disruptive technologies, including AI, big data, cloud, and cybersecurity, among others, to digitally transform its operations. The annual ICT spending of IAG is estimated at $215.9 million for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. IAG is a general insurance company operating in Australia and New Zealand. In Australia, the company’s...
-
Sector Analysis
![]()
United Kingdom (UK) Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2023 Update
United Kingdom (UK) Source Tourism Market Report Overview The United Kingdom source tourism market witnessed 68.07 million outbound trips and 129.08 million domestic trips in 2022. Domestic travel saw a YoY increase in 2022 due to the easing of pandemic restrictions and greater confidence in relation to the pandemic. This confidence caused an uptick in predominantly international travel as well as domestic travel. The total number of domestic return trips is expected to rebound to well above pre-pandemic levels by...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.